Lv2
166 积分 2025-02-16 加入
Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study
10天前
已完结
Circulating Tumour DNA Positivity Predicts Shorter Survival for Patients with High-grade pT1 Urothelial Bladder Carcinoma
1个月前
已完结
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update
3个月前
已完结
PDE5A(+) cancer-associated fibroblasts enhance immune suppression in gastric cancer
4个月前
已完结
IFI27 enhances bladder cancer immunotherapy response by modulating regulatory T cell enrichment
9个月前
已完结
Long-term Outcome of Patients with Frequently Recurrent Non–muscle-invasive Bladder Carcinoma Treated with One Perioperative Plus Four Weekly Instillations of Mitomycin C Followed by Monthly Bacillus Calmette-Guérin (BCG) or Alternating BCG and Interferon-α2b Instillations: Prospective Randomised FinnBladder-4 Study
9个月前
已完结
IFI27 enhances bladder cancer immunotherapy response by modulating regulatory T cell enrichment
10个月前
已完结
Interferon-stimulated gene IFI27 as a multifaceted candidate target in precision medicine
10个月前
已完结
Data from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
10个月前
已关闭
Cancer Research Communications
10个月前
已完结
皖公网安备34019202002308
